Bionaut Labs | November 29, 2022
Bionaut Labs, the company that uses microscale robots to revolutionize the treatment of central nervous system diseases and disorders, announced $43.2M in a Series B round of financing led by Khosla Ventures, bringing the company’s total financing raised to date to $63.2 million. Also participating in the round are new investors Deep Insight, OurCrowd, PSPRS, Sixty Degree Capital, Dolby Family Ventures, GISEV Family Ventures, What if Ventures, Tintah Grace and Gaingels, along with all existing investors - Upfront Ventures, BOLD Capital Partners, Revolution VC, and Compound.
Many diseases of the brain and central nervous system are hard to treat because it is difficult to deliver therapeutics beyond the blood-brain barrier and reach deep locations in the midbrain with precision. Through magnetic propulsion, Bionauts™ can navigate the depths of the human body to deliver drugs locally, generating efficacy and avoiding side effects and toxicity from systemically delivered drugs. By reaching the midbrain safely through novel routes, Bionaut Labs aims to develop solutions to treat the most debilitating conditions including Parkinson’s disease and Huntington's disease, malignant glioma and hydrocephalus.
Funds will be used to advance clinical development of the company’s lead programs against malignant glioma brain tumors and Dandy-Walker Syndrome (a rare pediatric neurological disorder). Funds will also support further development of its proprietary Bionaut™ treatment platform, allowing future expansion of clinical targets and progression through Bionaut’s two accelerated FDA designations. Bionaut Labs will release major pre-clinical data packages from IDE and IND enabling studies in 2023, with the goal of initiating human clinical trials in 2024.
“There has been a dearth of innovation around treatments for conditions that cause tremendous suffering, in large part because past failures have discouraged even the best of researchers. Bionaut Labs remains committed to finding new ways to treat these devastating diseases, which are long overdue for a breakthrough.”
Michael Shpigelmacher, co-founder and CEO, Bionaut Labs
Bionaut Labs is co-founded by two robotics entrepreneurs, Michael Shpigelmacher and Aviad Maizels, who previously co-founded PrimeSense, the company that developed the facial recognition tech behind iPhone’s FaceID. Its leadership and medical team consists of experts across robotics, neuroscience, biology and drug development.
“We are extremely excited about the transformative potential Bionaut presents in treating debilitating neurological disorders,” said Vinod Khosla, founder of Khosla Ventures. “Anatomically precise treatment will make traditionally-used methods seem archaic, and Bionaut is at the forefront of this movement.”
“Bionaut Labs tackles a complex pharmaceutical problem which many companies have failed to address in the past,” said Giammaria Giuliani, director of the GISEV Family Office. “As pioneers of micro-robotics for CNS treatment, the company enjoys a strong first-mover advantage and carries great promise.”
As neurodegeneration continues to grow in prevalence in the aging global population, Bionaut Labs offers unprecedented therapeutic access to the brain and other hard-to-reach locations in the body, diagnosing and treating diseases that were previously unreachable. Bionaut Labs will transform the way the biopharmaceutical industry develops treatments by offering a mechanism to engineer the therapeutic index for optimal efficacy and safety.
About Bionaut Labs
Bionaut Labs is a biotech company pioneering precision micro-technology with the deployment of microscale robots to remove the barriers of localized treatment and detection of diseases. Magnetic propulsion-controlled Bionauts navigate to deep locations in the human body and brain safely and precisely through non-linear 3D trajectories, making Bionaut Labs the first to access the midbrain through previously inaccessible anatomical routes. Bionauts can perform localized treatment, detection and precise medical procedures to deliver outcomes that were previously unattainable. The FDA has granted Bionaut Labs a Humanitarian Use Device designation for BNL-201, a micro-robot design to treat Dandy Walker Malformation, and an Orphan Drug Designation for BNL 101, a drug-device combination for treatment of malignant glioma.
TheraVet SA | September 19, 2022
TheraVet a pioneering company in the management of osteoarticular diseases in pets, announced today its participation in the annual congress of the European Society of Veterinary Orthopaedics and Traumatology which will be held from 21 to 24 September at the Acropolis in Nice, France.
With nearly 1000 participants, this event is the largest specialised congress in veterinary orthopaedics and traumatology in Europe, bringing together high-quality international speakers and therefore represents a prime showcase for the Company. ESVOT is chaired by Pr. Marc Balligand, who is also the President of the Scientific Advisory Board of TheraVet.
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris a with a US subsidiary in Texas.
In close collaboration with an international scientific board, THERAVET® has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on extremely promising clinical results, this line offers the possibility of a better, more convenient and more efficient orthopedic surgery.
CELL AND GENE THERAPY
Lunaphore and Nucleai | September 09, 2022
Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies.
“We are thrilled to announce the partnership with Lunaphore and combine Lunaphore’s best-in-class flagship COMET™, a hyperplex staining and imaging platform, with Nucleai’s ATOM platform that uniquely supports multiplex, IHC, and H&E data. This strategic partnership will allow us to utilize multiplex technology and provide a complete, actionable, and scalable solution to improve drug target discovery and development of our pharma and biotech partners.”
Avi Veidman, Chief Executive Officer of Nucleai
Mapping biological microenvironments with spatial mapping technology is an exciting area of discovery. Lunaphore’s novel COMET™ technology unlocks the power of immunofluorescence spatial biology with a robust and user-friendly system, permitting the use of any non-conjugated antibodies and enabling the wide adoption of spatial biology in laboratories. Nucleai has built a platform that makes spatial analysis scalable and operational, enabling the next generation of actionable insights from massive pathology data sets that have not been analyzed to their fullest potential and could provide significant value to pharmaceutical companies and diagnostic labs.
The partnership will utilize Lunaphore’s innovative COMET™ platform for hyperplex staining and imaging with Nucleai’s cutting-edge AI spatial models to derive new insights from tissue biopsies, including novel drug targets, mechanisms of action, and biomarkers to advance the field of precision medicine. The combined solutions will provide laboratories with an integrated end-to-end spatial biology workflow from automated, hyperplex sequential immunofluorescence staining and imaging to AI-enabled, state-of-the-art image processing, and data analytics. As part of the partnership, the companies also plan to develop predictive and prognostic spatial biomarker assays.
“Our partnership with Nucleai is based on our shared vision to advance next-generation spatial multiplex immunofluorescence imaging to accelerate drug and biomarker discovery and development,” said Déborah Heintze, Chief Marketing Officer of Lunaphore. “Connecting Nucleai’s solution with COMET™, we have the potential to more precisely characterize the immune system and disease microenvironment to provide deeper biological insights to drug developers.”
“Nucleai brings innovative spatial biology and machine learning platform (ATOM) to empower researchers with novel insights into drug discovery,” said Mridula Iyer, Ph.D., Vice President of Strategic Partnerships at Nucleai. “The technology is designed to unlock and analyze valuable data from pathology slides previously inaccessible, leading to the development of new precise targeted therapy that is important for patient outcomes. This collaboration is another example of how both Lunaphore and Nucleai are accelerating efforts to partner with pharmaceutical and biopharmaceutical companies, as well as medical research institutions and other biomedical organizations.”
COMET™ is a fully automated sequential immunofluorescence instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases. The technology has the ability to revolutionize clinical applications such as drug discovery and biomarker development.
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology that can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies.
Nucleai is an AI-powered spatial biology company with a mission to transform drug development and clinical treatment decisions by unlocking the power of pathology data. Nucleai provides pharmaceutical companies, Contract Research Organizations, and diagnostics laboratories with a state-of-the-art AI platform to improve clinical trials and clinical decision-making.